相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Thomas Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myeloma
Smith Giri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Alessandro Busca et al.
BLOOD ADVANCES (2022)
Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials
Rajshekhar Chakraborty et al.
CANCER (2022)
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
Julie O'Neal et al.
LEUKEMIA (2022)
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Adam D. Cohen et al.
BLOOD CANCER JOURNAL (2022)
Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
Ricardo D. Parrondo et al.
BLOOD CANCER JOURNAL (2022)
Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma
Nina Shah et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2022)
Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions
Samer Al Hadidi et al.
JAMA ONCOLOGY (2022)
Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).
He Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Beyond BCMA: Outcomes of relapsed/refractory multiple myeloma after progression on anti-BCMA T cell redirecting therapy.
Sankalp Arora et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access.
Taxiarchis Kourelis et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
Doris K. Hansen et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cytotoxic CD8+T cells in cancer and cancer immunotherapy
Hans Raskov et al.
BRITISH JOURNAL OF CANCER (2021)
Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study
Maria-Victoria Mateos et al.
BLOOD (2021)
Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis
Andrzej Jakubowiak et al.
BLOOD (2021)
Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T
Oliver Van Oekelen et al.
BLOOD (2021)
Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Sham Mailankody et al.
BLOOD (2021)
Updated Clinical and Correlative Results from the Phase I CRB402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma
Noopur S. Raje et al.
BLOOD (2021)
Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
Nina Shah et al.
BLOOD (2021)
Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study
Paula Rodriguez-Otero et al.
BLOOD (2021)
Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
Sham Mailankody et al.
BLOOD (2021)
Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma
Andrew J. Cowan et al.
BLOOD (2021)
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Parameswaran Hari et al.
BLOOD (2021)
Rethinking mechanisms of neurotoxicity with BCMA directed therapy
Ghulam Rehman Mohyuddin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis
Ghulam Rehman Mohyuddin et al.
EUROPEAN JOURNAL OF CANCER (2021)
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Oliver Van Oekelen et al.
NATURE MEDICINE (2021)
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
Matteo C. Da Via et al.
NATURE MEDICINE (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Mehmet Kemal Samur et al.
NATURE COMMUNICATIONS (2021)
The mutagenic impact of melphalan in multiple myeloma
Francesco Maura et al.
LEUKEMIA (2021)
CAR T-cell therapy in multiple myeloma: more room for improvement
Phaik Ju Teoh et al.
BLOOD CANCER JOURNAL (2021)
Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.
Luciano J. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
Larry D. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Sundar Jagannath et al.
BLOOD CANCER JOURNAL (2021)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
Nisha S. Joseph et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo et al.
LANCET HAEMATOLOGY (2020)
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
Elizabeth L. Siegler et al.
FRONTIERS IN IMMUNOLOGY (2020)
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
Gils Roex et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Philipp Karschnia et al.
BLOOD (2019)
Neurological toxicities associated with chimeric antigen receptor T-cell therapy
Daniel B. Rubin et al.
BRAIN (2019)
Manufacturing chimeric antigen receptor T cells: issues and challenges
Claire Roddie et al.
CYTOTHERAPY (2019)
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh et al.
NATURE (2019)
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Margot J. Pont et al.
BLOOD (2019)
The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma
Daniel Feinberg et al.
CELLULAR IMMUNOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Andrea Schmidts et al.
BLOOD ADVANCES (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Kevin M. Friedman et al.
HUMAN GENE THERAPY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction A Systematic Review and Meta-analysis
Binod Dhakal et al.
JAMA ONCOLOGY (2018)
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Michael M. Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Shinichi Makita et al.
CANCER SCIENCE (2017)
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
Yu-Tzu Tai et al.
BLOOD (2016)
Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer
Chuan Jin et al.
EMBO MOLECULAR MEDICINE (2016)
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
Claudia Zelle-Rieser et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
CAR models: next-generation CAR modifications for enhanced T-cell function
Daniel Abate-Daga et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay et al.
LANCET ONCOLOGY (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Sarah A. Laurent et al.
NATURE COMMUNICATIONS (2015)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma
Roman Hajek et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
B lymphocyte function in multiple myeloma: Analysis of T cell- and monocyte-dependent antibody production
Jørgen Peterson et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
分享论文
